In a strategic move to expand its specialty biopharmaceuticals portfolio, Meitheal Pharmaceuticals has acquired the North American rights to CONTEPO™ (fosfomycin for injection) from Nabriva Therapeutics. The announcement, made on July 18, 2024, marks a significant step in Meitheal’s efforts to address the growing concern of antibiotic resistance.
CONTEPO™, a novel intravenous antibiotic, has shown promising results against multi-drug resistant (MDR) strains that cause complicated urinary tract infections (cUTI). With its unique mechanism of action, CONTEPO™ could potentially fill critical gaps in the current antibiotic treatment landscape.
Tom Shea, Chief Executive Officer of Meitheal, emphasized the strategic importance of this acquisition, stating, “The addition of CONTEPO™ to our robust product portfolio provides us with a novel therapeutic with the potential to address a significant unmet need around increasing antibiotic resistance.”
Key points of the acquisition include:
- Meitheal gains North American rights to CONTEPO™, including development and regulatory activities, intellectual property rights, and related technology.
- Nabriva Therapeutics will receive payment upon closing and a royalty on net U.S. sales of CONTEPO™.
- A New Drug Application (NDA) for CONTEPO™ is currently pending with the U.S. Food and Drug Administration (FDA), with a decision expected later this year.
- If approved, Meitheal plans to establish a full commercial marketing and sales organization, along with a medical science liaison team to support clinicians.
The acquisition of CONTEPO™ adds to Meitheal’s growing portfolio of specialty biopharmaceuticals, following their commercial licensing agreement for XTMAB-16 in 2023. As a fully integrated biopharmaceutical company, Meitheal is well-positioned to navigate the final stages of the regulatory process and, if approved, ensure a consistent supply of this innovative antibiotic.
With an estimated three million cases of Gram-negative cUTIs treated annually in U.S. hospitals, and approximately 40% suspected to be caused by resistant strains, CONTEPO™ could play a crucial role in addressing this serious health threat.
As antibiotic resistance continues to pose challenges in healthcare, Meitheal’s acquisition of CONTEPO™ represents a significant step towards providing new treatment options for patients with complicated urinary tract infections.
Read the press release on Business Wire
—-
This article was originally published on iBIO NewsBrief. Gain a head start on your day with iBIO NewsBrief. Subscribe to receive top industry headlines delivered straight to your inbox.